ELF5 and neoplasm: Conditions that upregulate ELF5 expression, for example continuous endocrine therapy [19], or increased exposure to RANKL once resident in bone [17], may drive phenotypic conversion to an endocrine-resistant state via the remaking of the cell-fate decisions taken by the tumour initiating cells.